Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Tango Therapeutics (TNGX) EBITDA Margin: 2020-2025

Historic EBITDA Margin for Tango Therapeutics (TNGX) over the last 5 years, with Sep 2025 value amounting to 26.15%.

  • Tango Therapeutics' EBITDA Margin rose 30941.00% to 26.15% in Q3 2025 from the same period last year, while for Sep 2025 it was -165.91%, marking a year-over-year increase of 13531.00%. This contributed to the annual value of -309.38% for FY2024, which is 4149.00% down from last year.
  • Latest data reveals that Tango Therapeutics reported EBITDA Margin of 26.15% as of Q3 2025, which was up 102.03% from -1,287.87% recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' EBITDA Margin registered a high of 26.15% during Q3 2025, and its lowest value of -1,287.87% during Q2 2025.
  • Its 3-year average for EBITDA Margin is -492.35%, with a median of -459.66% in 2023.
  • In the last 5 years, Tango Therapeutics' EBITDA Margin soared by 30,979bps in 2023 and then plummeted by 113,918bps in 2025.
  • Over the past 5 years, Tango Therapeutics' EBITDA Margin (Quarterly) stood at -398.90% in 2021, then crashed by 3,643bps to -435.33% in 2022, then slumped by 11,514bps to -550.47% in 2023, then crashed by 44,322bps to -993.68% in 2024, then spiked by 30,941bps to 26.15% in 2025.
  • Its EBITDA Margin was 26.15% in Q3 2025, compared to -1,287.87% in Q2 2025 and -788.76% in Q1 2025.